Investigating Combination Therapy with an Oral Apelin Receptor Agonist to Increase the Efficacy of Incretin Drugs for Weight Loss
Time: 5:15 pm
day: Conference Day One
Details:
- Focusing on strategies for combining oral GLP-1s with complementary mechanisms to achieve injectable-like weight loss with improved body composition
- Reviewing pre-clinical data showing that azelaprag, a first-in-class apelin receptor agonist that improved muscle metabolism in older people in a Ph1b study, fully restores body weight, body composition, and muscle function to that of lean controls
- Highlighting the potential of azelaprag to increase weight loss and improve body composition in older obese patients in a Ph2 trial of azelaprag + tirzepatide coadministration
